326 related articles for article (PubMed ID: 3162758)
1. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
Zamora JM; Pearce HL; Beck WT
Mol Pharmacol; 1988 Apr; 33(4):454-62. PubMed ID: 3162758
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
3. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine.
Beck WT; Cirtain MC; Glover CJ; Felsted RL; Safa AR
Biochem Biophys Res Commun; 1988 Jun; 153(3):959-66. PubMed ID: 2898941
[TBL] [Abstract][Full Text] [Related]
4. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
5. Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells.
Zamora JM; Beck WT
Biochem Pharmacol; 1986 Dec; 35(23):4303-10. PubMed ID: 3466591
[TBL] [Abstract][Full Text] [Related]
6. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
Inaba M; Nagashima K
Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine.
Sertel S; Fu Y; Zu Y; Rebacz B; Konkimalla B; Plinkert PK; Krämer A; Gertsch J; Efferth T
Biochem Pharmacol; 2011 Mar; 81(6):723-35. PubMed ID: 21219884
[TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Pereira E; Tarasiuk J; Garnier-Suillerot A
Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
[TBL] [Abstract][Full Text] [Related]
9. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
[TBL] [Abstract][Full Text] [Related]
10. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
Tsuruo T
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
[TBL] [Abstract][Full Text] [Related]
11. Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.
Hill BT; Hosking LK
Cancer Chemother Pharmacol; 1994; 33(4):317-24. PubMed ID: 8281626
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle.
Skovsgaard T; Danø K; Nissen NI
Cancer Treat Rev; 1984 Mar; 11 Suppl A():63-72. PubMed ID: 6375864
[No Abstract] [Full Text] [Related]
13. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
14. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.
Tsuruo T
Cancer Treat Rep; 1983 Oct; 67(10):889-94. PubMed ID: 6354436
[TBL] [Abstract][Full Text] [Related]
15. [Studies on the mechanism of multidrug resistance].
Inaba M
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):807-14. PubMed ID: 3471182
[TBL] [Abstract][Full Text] [Related]
16. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.
Thimmaiah KN; Horton JK; Qian XD; Beck WT; Houghton JA; Houghton PJ
Cancer Commun; 1990; 2(7):249-59. PubMed ID: 2378785
[TBL] [Abstract][Full Text] [Related]
17. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission.
Harker WG; Bauer D; Etiz BB; Newman RA; Sikic BI
Cancer Res; 1986 May; 46(5):2369-73. PubMed ID: 3754487
[TBL] [Abstract][Full Text] [Related]
18. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines.
Qian XD; Beck WT
Cancer Res; 1990 Feb; 50(4):1132-7. PubMed ID: 1967551
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Berlion M; Arvelo F; Leonce S; Bourgeois Y; Rigaudy P; Bizzari JP; Poupon MF
In Vivo; 1993; 7(5):399-405. PubMed ID: 7906553
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of interaction of vinca alkaloids with tubulin: catharanthine and vindoline.
Prakash V; Timasheff SN
Biochemistry; 1991 Jan; 30(3):873-80. PubMed ID: 1988072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
